Loading, Please Wait...

CST: 12/11/2019 02:31:53   

ChromaDex Corporation Reports Second Quarter 2019 Financial Results   

96 Days ago

Second Quarter 2019 Net Revenues Increased by 42% to $11.1 Million

Second Quarter 2019 Highlights vs. Second Quarter 2018

  • Strong growth in net sales to $11.1 million, significantly higher gross margins, and improved marketing efficiency year-over-year
  • TRU NIAGEN net sales of $8.7 million, a 17% increase sequentially and a 134% increase year-over-year
  • Global expansion continued with initial cross-border sales in China and Japan, and new Canadian retail distribution in Whole Foods Ontario locations
  • New clinical study further demonstrated safety of sustained NIAGEN supplementation at recommended daily serving as well as statistically significant sustained blood NAD+ levels

LOS ANGELES, Aug. 07, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) today reported second quarter 2019 financial results.

“We successfully continue to build our global TRU NIAGEN brand and consequentially had another quarter strengthening our business momentum, economics and brand foundation,” said ChromaDex CEO Rob Fried.

Results of operations for the three months ended June 30, 2019

For the three months ended June 30, 2019 (“Q2 2019”), ChromaDex reported net sales of $11.1 million, up 42% compared to $7.8 million in the second quarter of 2018 ("Q2 2018"). The increase in Q2 2019 revenues was driven by growth in sales of TRU NIAGEN.

Gross margin increased by 700 basis points to 56.3% for Q2 2019 compared to 49.3% in Q2 2018.  The increase in gross margin was driven by the positive impact of TRU NIAGEN consumer product sales. 

Operating expenses increased by $1.7 million to $13.4 million in Q2 2019, compared to $11.8 million in Q2 2018. The increase in operating expenses was driven by an increase of $0.5 million of advertising and marketing and $1.3 million of general and administrative expense, partially offset by $0.3 million of lower R&D expense.  The increase in general and administrative expense was driven by higher royalties to patent holders and higher legal expense.

The net loss for the second quarter of 2019 was $7.8 million or ($0.14) per share as compared to a net loss of $8.1 million or ($0.15) per share for the second quarter of 2018.  For Q2 2019, the reported loss was negatively impacted by a non-cash charge of $1.8 million related to equity-based compensation and $0.6 million of costs related to the issuance of $10.0 million convertible notes to certain investors which were recorded as a debt discount and amortized as interest expense.

Adjusted EBITDA excluding total legal expense, a non-GAAP measure, was ($2.1) million for Q2 2019, compared to ($3.9) million for Q2 2018.  Sequentially, Adjusted EBITDA excluding total legal expense improved by $0.6 million compared to ($2.7) million for the three months ended March 31, 2019.  The $0.6 million improvement was primarily driven by higher gross margins and higher sales.  Adjusted EBITDA excluding total legal expense for the three months ended December 31, 2018 and September 30, 2018 were ($4.0) million and ($4.3) million, respectively.

ChromaDex defines Adjusted EBITDA excluding total legal expense as net income or (loss) which is adjusted for interest, income tax, depreciation, amortization, non-cash stock compensation costs and total legal expense. 

For the second quarter of 2019, the net cash used in operating activities was $9.0 million versus $6.5 million for the same period in the prior year.  The Company ended the second quarter of 2019 with cash of $19.8 million, which includes the $10.0 million of proceeds from the issuance of convertible notes.

2019 Outlook

Looking forward, the Company expects revenue growth to be driven primarily by its U.S. ecommerce and Watsons international business, as well as the launch of TRU NIAGEN® with other distributors in certain new international markets. The Company expects continued gross margin improvement and lower selling, marketing and advertising as well as general and administrative expenses as a percentage of net sales.

Investor Conference Call

ChromaDex management will host an investor conference call to discuss the second quarter results and provide a general business update on Wednesday, August 7, at 4:30pm ET.

Participants should call in at least 10 minutes prior to the call. The dial-in information is as follows:

Date: Wed., August 7, 2019
Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time) 
Toll-free dial-in number: 1-866-211-3191
International dial-in number: 1-647-689-6604
Conference ID: 3774159
Webcast link: ChromaDex Q2 2019 Earnings Conference Call

The conference call will be broadcast live and available for replay here and via the investor relations section of the Company’s website at www.chromadex.com.

A replay of the conference call will be available after 7:30 p.m. ET.

Toll-free replay number: 1-800-585-8367
International replay number: 1-416-621-4642
Replay ID: 3774159

The earnings press release, and its accompanying financial exhibits, will be available on the Investor Relations section of the Company website, www.chromadex.com.

About Non-GAAP Financial Measures:

ChromaDex’s non-GAAP financial measures exclude interest, income tax, depreciation, amortization, non-cash share-based compensation costs and total legal expense for adjusted EBITDA excluding total legal expense.  ChromaDex used these non-GAAP measures when evaluating its financial results as well as for internal resource management, planning and forecasting purposes. These non-GAAP measures should not be viewed in isolation from or as a substitute for ChromaDex’s financial results in accordance with GAAP. Reconciliation of GAAP to non-GAAP measures are attached to this press release.

About ChromaDex:

ChromaDex Corp.  is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

Important Note on Forward Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include the quotation from ChromaDex’s Chief Executive Officer, and statements related to future revenue growth being driven by ChromaDex’s U.S. ecommerce and Watsons’ international business, launching TRU NIAGEN in certain new international markets, the expectations of gross margin improvement, and the expectations of lower selling, marketing and advertising expenses and lower general and administrative expenses as a percentage of net sales. Other risks that contribute to the uncertain nature of the forward-looking statements are reported in our most recent Forms 10-Q and 10-K as filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

ChromaDex Investor Relations Contact:

Brianna Gerber, Sr. Director of FP&A and Investor Relations

949-419-0288 ext. 127

briannag@chromadex.com

ChromaDex Media Contact:

Alex Worsham, Director of Strategic Partnerships

310-388-6706 ext. 689

alexw@chromadex.com

ChromaDex Corporation


ChromaDex Corporation and Subsidiaries 
Condensed Consolidated Statements of Operations 
For the Three Month Periods Ended June 30, 2019 and June 30, 2018
(In thousands, except per share data)      
       
  June 30, 2019 June 30, 2018  
       
Sales, net $     11,101     $   7,803     
Cost of sales     4,847         3,957     
       
Gross profit     6,254         3,846     
       
Operating expenses:      
Sales and marketing     4,308         3,773     
Research and development     1,069         1,414     
General and administrative     7,932         6,596     
Other     125         -     
Operating expenses     13,434         11,783     
       
Operating loss     (7,180   )     (7,937  )  
       
Nonoperating income (expense):      
Interest expense, net     (575   )     (48  )  
Other     -         (65  )  
Nonoperating income (expense):     (575   )     (113  )  
       
Net loss $     (7,755   ) $   (8,050  )  
       
Basic and diluted loss per common share $     (0.14   ) $   (0.15  )  
       
Basic and diluted weighted average common shares outstanding     55,539         54,892     

See Notes to Condensed Consolidated Financial Statements in Part I of ChromaDex's Quarterly Report on Form 10-Q filed with Securities and Exchange Commission on August 7, 2019. 


ChromaDex Corporation and Subsidiaries 
Condensed Consolidated Balance Sheets 
June 30, 2019 and December 31, 2018 
(In thousands, except per share data) 
       
  Jun. 30, 2019 Dec. 31, 2018  
Assets      
       
Current Assets      
Cash, including restricted cash of $0.2 million and $0.2 million, respectively $     19,760     $   22,616     
Trade receivables, net of allowances of $0.5 million and $0.5 million, respectively;      
  Receivables from Related Party: $1.6 million and $0.7 million, respectively     5,740         4,359     
Contract assets     52         56     
  Receivable held at escrow, net of allowance of $0.2 million and $0.1 million, respectively     553         677     
Inventories     10,714         8,249     
Prepaid expenses and other assets     706         577     
Total current assets     37,525         36,534     
       
Leasehold Improvements and Equipment, net     3,737         3,585     
Intangible Assets, net     1,434         1,547     
Right of Use Assets     1,190         -     
Other Long-term Assets     656         566     
       
Total assets $     44,542     $   42,232     
       
Liabilities and Stockholders' Equity      
       
Current Liabilities      
Accounts payable $     9,323     $   9,548     
Accrued expenses     3,643         4,444     
Convertible notes     9,987         -     
Current maturities of operating lease obligations     662         -     
Current maturities of finance lease obligations     303         173     
Contract liabilities and customer deposits     293         275     
Total current liabilities     24,211         14,440     
       
Deferred Revenue     3,873         -     
Operating Lease Obligations, Less Current Maturities     1,192         -     
Finance Lease Obligations, Less Current Maturities     121         137     
Deferred Rent     -         477     
       
Total liabilities     29,397         15,054     
       
Commitments and Contingencies      
Stockholders' Equity      
Common stock, $.001 par value; authorized 150,000 shares;       
  issued and outstanding June 30, 2019 55,384 shares and      
  December 31, 2018 55,089 shares     55         55     
Additional paid-in capital     120,935         116,876     
Accumulated deficit     (105,845   )     (89,753  )  
Total stockholders' equity     15,145         27,178     
Total liabilities and stockholders' equity $     44,542     $   42,232     

See Notes to Condensed Consolidated Financial Statements in Part I of ChromaDex's Quarterly Report on Form 10-Q filed with Securities and Exchange Commission on August 7, 2019. 


ChromaDex Corporation and Subsidiaries 
Reconciliation of Non-GAAP Financial Measures 
(In thousands) 
 
  Three months ended
  Mar. 31, 2018 Jun. 30, 2018 Sep. 30, 2018 Dec. 31, 2018 Mar. 31, 2019 Jun. 30, 2019
     
Net loss, as reported $   (8,443  ) $   (8,050  ) $   (8,605  ) $   (8,218  ) $   (8,337  ) $     (7,755   )
  Adjustments:            
  Interest (income) expense     44        48        9        (22  )     (35  )     575    
  Depreciation     121        146        169        171        173        190    
  Amortization of intangibles     58        58        59        60        61        61    
  Amortization of right of use assets     -        -        -        -        138        141    
  Share-based compensation     1,258        1,811        1,317        1,985        2,029        1,759    
Adjusted EBITDA $   (6,962  ) $   (5,987  ) $   (7,051  ) $   (6,024  ) $   (5,971  ) $     (5,029   )
             
  Total legal expense     2,973        2,079        2,723        2,045        3,250        2,926    
   
Adjusted EBITDA excluding total legal expense $   (3,989  ) $   (3,908  ) $   (4,328  ) $   (3,979  ) $   (2,721  ) $     (2,103   )
 

 

Is your business listed correctly on America’s largest city directory network of 1,000 portals?